Substitute preparations for blood coagulation disorders (hemophilia, TTP, antidote, paroxysmal nocturnal hemoglobinuria (PNH)) belong to this category. To date, the G-BA has assessed xx such products in xx procedures. In the xx observed subpopulations, xx% have seen a major, XX% a considerable and XX% a minor additional benefit in relation to the comparative therapy. A non-quantifiable additional benefit has been proved for XX% of the subpopulations.

By contrast, no additional benefit has been proved for XX% of the subpopulations weighted by patient share per resolution. In total, this includes xx% of the xx million patients relevant for treatment with the assessed medicinal products.